Skip to Content
Søk Menu

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

A comprehensive analysis of Venetoclax-Obinutuzumab (Ven-Obi) in treating chronic lymphocytic leukemia (CLL) reveals its effectiveness and tolerability across different patient profiles.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Paolo Ghia

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Paolo Ghia
CLLEHA24 Play the Video 02:42
Alessandra Tedeschi

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

/ Alessandra Tedeschi
CLLEHA24 Play the Video 01:52

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymfom Play the Video 01:08
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video 03:32
Jason Westin

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

/ Jason Westin
ASH23B-celle lymfom Play the Video 2:05
Eva Birgitte Leinøe

Undiagnosed and Unrecognized Patients with a High Bleeding Score

/ Eva Birgitte Leinøe
ASH23 Play the Video 03:43
Pieter Sonneveld

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Pieter Sonneveld
ASH23Myelom Play the Video 05:04
Jeff P. Sharman

No increase risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Jeff P. Sharman
ASH23CLL Play the Video 1:45
Back to top